Drug combination and nanooncology for improvement in the treatment of breast cancer: a review

Detalhes bibliográficos
Autor(a) principal: Faria, Raquel Santos
Data de Publicação: 2021
Outros Autores: Souza, Danielle Galdino de, Pacheco, Thyago José Arruda, Silva, Franciéle de Matos da, Silva, Victor Carlos Mello da, Lima, Luiza Ianny de
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Research, Society and Development
Texto Completo: https://rsdjournal.org/index.php/rsd/article/view/14098
Resumo: Optimizing drug combination treatment has been an area of interest for a while, from the beginning with the emergence of the POMP regime. The ability to improve drug combinations for cancer treatment comes up against the possibility of several limitations, such as the lack of specificity of the drugs, generating systemic toxic effects, and also the great possibility of generating tumor cells resistant to the drugs. The development of nanooncology offers advances in new alternatives for the treatment of cancer, especially breast cancer. The strategy of using drugs combined in a nanocarrier for the treatment of breast cancer has proven to be quite effective, taking into account that breast cancer has long shown a good response with therapeutic combinations. In this work, we present a review of some examples of nanoformulations developed with the combination of drugs doxorubicin and/or paclitaxel aimed for the treatment of breast cancer. Also the future perspectives of nanotechnology in the drug combination.
id UNIFEI_20dd641c72ac1417202ae3f145124d86
oai_identifier_str oai:ojs.pkp.sfu.ca:article/14098
network_acronym_str UNIFEI
network_name_str Research, Society and Development
repository_id_str
spelling Drug combination and nanooncology for improvement in the treatment of breast cancer: a reviewCombinación de fármacos y nanooncología para mejorar el tratamiento del cáncer de mama: una revisiónCombinação de drogas e nanooncologia para melhoria no tratamento do câncer de mama: uma revisãoCâncer de mamaQuimioterapiaNanomedicinaNanotecnologia.Cáncer de mamaQuimioterapiaNanomedicinaNanotecnología.Breast cancerChemotherapyNanomedicineNanotechnology.Optimizing drug combination treatment has been an area of interest for a while, from the beginning with the emergence of the POMP regime. The ability to improve drug combinations for cancer treatment comes up against the possibility of several limitations, such as the lack of specificity of the drugs, generating systemic toxic effects, and also the great possibility of generating tumor cells resistant to the drugs. The development of nanooncology offers advances in new alternatives for the treatment of cancer, especially breast cancer. The strategy of using drugs combined in a nanocarrier for the treatment of breast cancer has proven to be quite effective, taking into account that breast cancer has long shown a good response with therapeutic combinations. In this work, we present a review of some examples of nanoformulations developed with the combination of drugs doxorubicin and/or paclitaxel aimed for the treatment of breast cancer. Also the future perspectives of nanotechnology in the drug combination.La optimización del tratamiento de combinación de fármacos ha sido un área de interés durante un tiempo, desde el principio con la aparición del régimen POMP. La capacidad de mejorar las combinaciones de fármacos para el tratamiento del cáncer se enfrenta a la posibilidad de varias limitaciones, como la falta de especificidad de los fármacos, que genera efectos tóxicos sistémicos, y también la gran posibilidad de generar células tumorales resistentes a los fármacos. El desarrollo de la nanooncología ofrece avances en nuevas alternativas para el tratamiento del cáncer, especialmente el cáncer de mama. La estrategia de utilizar fármacos combinados en un nanoportador para el tratamiento del cáncer de mama ha demostrado ser bastante eficaz, teniendo en cuenta que el cáncer de mama ha mostrado desde hace mucho tiempo una buena respuesta con combinaciones terapéuticas. En este trabajo presentamos una revisión de algunos ejemplos de nanoformulaciones desarrolladas con la combinación de fármacos doxorrubicina y / o paclitaxel dirigidos al tratamiento del cáncer de mama. También las perspectivas de futuro de la nanotecnología en la combinación de fármacos.A otimização do tratamento de combinação de medicamentos tem sido uma área de interesse há algum tempo, desde o início com o surgimento do regime POMP. A capacidade de melhorar as combinações de medicamentos para o tratamento do câncer esbarra na possibilidade de várias limitações, como a falta de especificidade dos medicamentos, gerando efeitos tóxicos sistêmicos, e também a grande possibilidade de gerar células tumorais resistentes aos medicamentos. O desenvolvimento da nanooncologia oferece avanços em novas alternativas para o tratamento do câncer, principalmente do câncer de mama. A estratégia de usar medicamentos combinados em um nanocarreador para o tratamento do câncer de mama tem se mostrado bastante eficaz, levando-se em consideração que o câncer de mama há muito apresenta uma boa resposta com combinações terapêuticas. Neste trabalho, apresentamos uma revisão de alguns exemplos de nanoformulações desenvolvidas com a combinação dos fármacos doxorrubicina e / ou paclitaxel voltados para o tratamento do câncer de mama. Também as perspectivas futuras da nanotecnologia na combinação de medicamentos.Research, Society and Development2021-04-16info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfhttps://rsdjournal.org/index.php/rsd/article/view/1409810.33448/rsd-v10i4.14098Research, Society and Development; Vol. 10 No. 4; e40710414098Research, Society and Development; Vol. 10 Núm. 4; e40710414098Research, Society and Development; v. 10 n. 4; e407104140982525-3409reponame:Research, Society and Developmentinstname:Universidade Federal de Itajubá (UNIFEI)instacron:UNIFEIenghttps://rsdjournal.org/index.php/rsd/article/view/14098/12829Copyright (c) 2021 Raquel Santos Faria; Danielle Galdino de Souza; Thyago José Arruda Pacheco; Franciéle de Matos da Silva; Victor Carlos Mello da Silva; Luiza Ianny de Limahttps://creativecommons.org/licenses/by/4.0info:eu-repo/semantics/openAccessFaria, Raquel Santos Souza, Danielle Galdino dePacheco, Thyago José ArrudaSilva, Franciéle de Matos daSilva, Victor Carlos Mello da Lima, Luiza Ianny de 2021-04-25T11:21:26Zoai:ojs.pkp.sfu.ca:article/14098Revistahttps://rsdjournal.org/index.php/rsd/indexPUBhttps://rsdjournal.org/index.php/rsd/oairsd.articles@gmail.com2525-34092525-3409opendoar:2024-01-17T09:35:18.102297Research, Society and Development - Universidade Federal de Itajubá (UNIFEI)false
dc.title.none.fl_str_mv Drug combination and nanooncology for improvement in the treatment of breast cancer: a review
Combinación de fármacos y nanooncología para mejorar el tratamiento del cáncer de mama: una revisión
Combinação de drogas e nanooncologia para melhoria no tratamento do câncer de mama: uma revisão
title Drug combination and nanooncology for improvement in the treatment of breast cancer: a review
spellingShingle Drug combination and nanooncology for improvement in the treatment of breast cancer: a review
Faria, Raquel Santos
Câncer de mama
Quimioterapia
Nanomedicina
Nanotecnologia.
Cáncer de mama
Quimioterapia
Nanomedicina
Nanotecnología.
Breast cancer
Chemotherapy
Nanomedicine
Nanotechnology.
title_short Drug combination and nanooncology for improvement in the treatment of breast cancer: a review
title_full Drug combination and nanooncology for improvement in the treatment of breast cancer: a review
title_fullStr Drug combination and nanooncology for improvement in the treatment of breast cancer: a review
title_full_unstemmed Drug combination and nanooncology for improvement in the treatment of breast cancer: a review
title_sort Drug combination and nanooncology for improvement in the treatment of breast cancer: a review
author Faria, Raquel Santos
author_facet Faria, Raquel Santos
Souza, Danielle Galdino de
Pacheco, Thyago José Arruda
Silva, Franciéle de Matos da
Silva, Victor Carlos Mello da
Lima, Luiza Ianny de
author_role author
author2 Souza, Danielle Galdino de
Pacheco, Thyago José Arruda
Silva, Franciéle de Matos da
Silva, Victor Carlos Mello da
Lima, Luiza Ianny de
author2_role author
author
author
author
author
dc.contributor.author.fl_str_mv Faria, Raquel Santos
Souza, Danielle Galdino de
Pacheco, Thyago José Arruda
Silva, Franciéle de Matos da
Silva, Victor Carlos Mello da
Lima, Luiza Ianny de
dc.subject.por.fl_str_mv Câncer de mama
Quimioterapia
Nanomedicina
Nanotecnologia.
Cáncer de mama
Quimioterapia
Nanomedicina
Nanotecnología.
Breast cancer
Chemotherapy
Nanomedicine
Nanotechnology.
topic Câncer de mama
Quimioterapia
Nanomedicina
Nanotecnologia.
Cáncer de mama
Quimioterapia
Nanomedicina
Nanotecnología.
Breast cancer
Chemotherapy
Nanomedicine
Nanotechnology.
description Optimizing drug combination treatment has been an area of interest for a while, from the beginning with the emergence of the POMP regime. The ability to improve drug combinations for cancer treatment comes up against the possibility of several limitations, such as the lack of specificity of the drugs, generating systemic toxic effects, and also the great possibility of generating tumor cells resistant to the drugs. The development of nanooncology offers advances in new alternatives for the treatment of cancer, especially breast cancer. The strategy of using drugs combined in a nanocarrier for the treatment of breast cancer has proven to be quite effective, taking into account that breast cancer has long shown a good response with therapeutic combinations. In this work, we present a review of some examples of nanoformulations developed with the combination of drugs doxorubicin and/or paclitaxel aimed for the treatment of breast cancer. Also the future perspectives of nanotechnology in the drug combination.
publishDate 2021
dc.date.none.fl_str_mv 2021-04-16
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv https://rsdjournal.org/index.php/rsd/article/view/14098
10.33448/rsd-v10i4.14098
url https://rsdjournal.org/index.php/rsd/article/view/14098
identifier_str_mv 10.33448/rsd-v10i4.14098
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv https://rsdjournal.org/index.php/rsd/article/view/14098/12829
dc.rights.driver.fl_str_mv https://creativecommons.org/licenses/by/4.0
info:eu-repo/semantics/openAccess
rights_invalid_str_mv https://creativecommons.org/licenses/by/4.0
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Research, Society and Development
publisher.none.fl_str_mv Research, Society and Development
dc.source.none.fl_str_mv Research, Society and Development; Vol. 10 No. 4; e40710414098
Research, Society and Development; Vol. 10 Núm. 4; e40710414098
Research, Society and Development; v. 10 n. 4; e40710414098
2525-3409
reponame:Research, Society and Development
instname:Universidade Federal de Itajubá (UNIFEI)
instacron:UNIFEI
instname_str Universidade Federal de Itajubá (UNIFEI)
instacron_str UNIFEI
institution UNIFEI
reponame_str Research, Society and Development
collection Research, Society and Development
repository.name.fl_str_mv Research, Society and Development - Universidade Federal de Itajubá (UNIFEI)
repository.mail.fl_str_mv rsd.articles@gmail.com
_version_ 1797052747769446400

Registros relacionados